ABMD-MSC

ABMD-MSC is an allogeneic cell therapy consisting of mesenchymal stromal cells (MSCs) harvested from the bone marrow of healthy donors. Developed by Sheba Medical Center, this therapeutic candidate is specifically designed for the treatment of chronic diabetic foot ulcers (DFU) and associated complications. MSCs are characterized by their ability to migrate to sites of injury and secrete a variety of bioactive molecules, including growth factors and anti-inflammatory cytokines, which collectively facilitate angiogenesis, modulate the immune response, and promote dermal fibroblast proliferation. The Phase 1 clinical evaluation focuses on the safety and efficacy of these cultured cells in improving wound closure rates and preventing lower limb amputations in diabetic patients with compromised healing capacities due to neuropathy or peripheral vascular disease.

Other names

Allogeneic Bone Marrow Derived Mesenchymal Stromal CellsBM-MSCsAllogeneic Bone Marrow-Derived Mesenchymal Stem Cells